United Arab Emirates (UAE) Aesthetic Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united arab emirates aesthetic devices market size is expected to grow from USD 174.72 million in 2025 to USD 196.64 million in 2026 and is forecast to reach USD 354.97 million by 2031 at 12.54% CAGR over 2026-2031. This report is Segmented by Device Type (Energy-Based Devices, Non-Energy-Based Devices), Application (Skin Resurfacing & Tightening, Body Contouring & Cellulite Reduction, Hair Removal, Tattoo & Pigmentation Removal, Breast Augmentation, and More), End User (Hospitals, Specialist Clinics, and More), and Geography (UAE). The Market Forecasts are Provided in Terms of Value (USD).

United Arab Emirates (UAE) Aesthetic Devices Market Trends and Insights

Booming Inbound Medical Tourism

The country attracted 691,000 medical tourists in 2023, with a sizeable portion seeking aesthetic care. Dubai Healthcare City issues specialized medical visas that streamline cross-border patient access. A government commitment to spend AED 112.7 billion on healthcare infrastructure by 2027 enhances supply capacity. Premium facilities, such as American Hospital Dubai and Aesthetics by King’s, offer market-integrated hotel-clinic experiences, reinforcing the UAE as a luxury destination for aesthetic devices. International patients expect state-of-the-art equipment, prompting providers to invest heavily in new platforms that justify premium pricing. Continued medical-tourism inflows stabilize revenue streams and elevate equipment refresh cycles to maintain brand reputations.

Rising Volume of Cosmetic Procedures

Procedure counts in Dubai doubled between 2022 and 2024, as social media visibility, wellness culture, and expanding male participation increased overall demand. Male patients accounted for 47% of interventions in 2024, narrowing a historical gender gap and broadening the patient base. Expenditure on surgical and nonsurgical services reached AED 300 million, underpinned by one of the world’s highest plastic-surgeon densities per capita. Treatment mix shifts toward body-contouring options instead of facial surgeries, mirroring consumer priorities for rapid results with minimal downtime. Higher procedure throughput directly increases the utilization of injectables, lasers, and emerging radio-frequency devices, sustaining long-term procurement cycles for clinics that must refresh their technology to remain competitive.

Lack of Insurance Reimbursement

Most aesthetic procedures remain elective and are excluded from health insurance plans, leading to out-of-pocket costs ranging from USD 5,000 to USD 50,000. Financing schemes help, but do not fully bridge affordability gaps for middle-income residents. Hospital procurement decisions often rely on insured volumes, so the absence of reimbursement shifts provider focus toward affluent clients and may restrict device rotation in public facilities.

Other drivers and restraints analyzed in the detailed report include:

• Device-Leasing Models Lowering CAPEX for Clinics
• Rising Disposable Income of UAE Residents
• Social Stigma Among Conservative Sub-Populations

Segment Analysis

The UAE aesthetic devices market size for non-energy systems held a 55.63% share in 2025, underscoring the popularity of injectables and micro-cannula delivery kits. The consistent appeal of botulinum toxin and dermal fillers keeps demand steady, thanks to their immediate visible outcomes and low downtime. Clinics bundle injectable sessions with adjunct treatments such as LED masks, creating cross-selling opportunities that strengthen supplier relationships.

Energy-based technologies collectively register faster growth, with radio-frequency equipment forecast to expand at a 17.38% CAGR through 2031. Consumers respond positively to the non-surgical skin-tightening and body-shaping effects. Vendors capitalize on this trend by integrating real-time temperature monitoring to enhance safety. Laser platforms maintain relevance for hair removal across mixed-phototype populations, while IPL devices gain adoption for pigment issues common in sun-exposed climates. Ultrasound-based lipolysis and cryolipolysis machines capture niche demand among patients unwilling to undergo invasive liposuction, and plasma-based devices find traction for eyelid rejuvenation. The Emirates Drug Establishment’s stringent but efficient certification process supports clinician confidence and promotes continued diversification within the UAE aesthetic devices market.

In the medium term, leasing programs enable smaller practices to experiment with multi-modal workstations that combine RF, ultrasound, and pulsed light. Suppliers differentiate by offering operator training and predictive maintenance, ensuring 24/7 uptime that aligns with consumer expectations for same-day appointments. As energy-based adoption expands, non-energy treatments will coexist rather than be displaced, creating complementary revenue streams for providers seeking to offer comprehensive aesthetic solutions.

Complete Report Scope:

• By Device Type
  • Energy-based Devices
    • Laser-based
    • Light-based (IPL)
    • Radio-frequency-based
    • Ultrasound-based
    • Cryolipolysis & Plasma-based
  • Non-energy-based Devices
    • Botulinum Toxin
    • Dermal Fillers & Threads
    • Chemical Peels
    • Microdermabrasion
    • Implants
    • Mesotherapy & Others
• By Application
  • Skin Resurfacing & Tightening
  • Body Contouring & Cellulite Reduction
  • Hair Removal
  • Tattoo & Pigmentation Removal
  • Breast Augmentation
  • Acne & Scar Treatment
  • Other Applications
• By End User
  • Hospitals
  • Specialist & Multi-specialty Clinics
  • Other End Users

List of Companies Covered in this Report:

• Abbvie
• Galderma
• Sisram Medical
• Candela Medical
• Bausch Health
• Cynosure
• Sciton
• Merz Pharma
• Cutera
• Fotona
• InMode
• Venus Concept
• Lumenis
• Lutronic
• Mentor Worldwide (J&J)
• Sientra
• Suneva Medical
• Revance Therapeutics
• Apyx Medical (Renuvion)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support